Advertisement

Journal of Inherited Metabolic Disease

, Volume 41, Issue 2, pp 263–275 | Cite as

Correlation between the molecular effects of mutations at the dimer interface of alanine–glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B6

  • Mirco Dindo
  • Elisa Oppici
  • Daniele Dell’Orco
  • Rosa Montone
  • Barbara CelliniEmail author
Original Article

Abstract

Primary hyperoxaluria type I (PH1) is a rare disease caused by the deficit of liver alanine–glyoxylate aminotransferase (AGT). AGT prevents oxalate formation by converting peroxisomal glyoxylate to glycine. When the enzyme is deficient, progressive calcium oxalate stones deposit first in the urinary tract and then at the systemic level. Pyridoxal 5′-phosphate (PLP), the AGT coenzyme, exerts a chaperone role by promoting dimerization, as demonstrated by studies at protein and cellular level. Thus, variants showing a destabilized dimeric structure should, in principle, be responsive to vitamin B6, a precursor of PLP. However, models to predict the extent of responsiveness of each variant are missing. We examined the effects of pathogenic interfacial mutations by combining bioinformatic predictions with molecular and cellular studies on selected variants (R36H, G42E, I56N, G63R, and G216R), in both their holo- (i.e., with bound PLP) and apo- (i.e., without bound PLP) form. We found that all variants displayed structural alterations mainly related to the apoform and consisting of an altered tertiary and quaternary structure. G216R also shows a strongly reduced catalytic efficiency. Moreover, all but G216R respond to vitamin B6, as shown by their increased specific activity and expression level in a cellular disease model. A global analysis of data unraveled a possible inverse correlation between the degree of destabilization/misfolding induced by a mutation and the extent of B6 responsiveness. These results provide a first explanation of factors influencing B6 response in PH1, a model possibly valuable for other rare diseases caused by protein deficits.

Abbreviations

AGT

Alanine–glyoxylate aminotransferase

PH1

Primary hyperoxaluria type I

PLP

Pyridoxal 5′ -phosphate

PNP

Pyridoxine 5′ -phosphate

PMP

Pyridoxamine 5′ -phosphate

PL

Pyridoxal

PN

Pyridoxine

PM

Pyridoxamine

PBS

Phosphate-buffered saline

KP

Potassium phosphate buffer

IFM

Immunofluorescence microscopy

CHO-GO

Chinese hamster ovary cells overexpressing glycolate oxidase

CD

Circular dichroism

Notes

Acknowledgements

This work was supported by grants from the Oxalosis and Hyperoxaluria Foundation (OHF2012 to BC). EO was supported by a fellowship from the Italian Ministery of Instruction University and Research (RBSI148BK3 to BC).

Compliance with ethical standards

The submitting author confirms that all authors provided information on Compliance with Ethics Guidelines in the manuscript.

Informed consent and animal right

This article contains no studies with human or animal subjects performed by any of the authors.

Competing interest statement

The submitting authors do not have any competing interest to declare.

Supplementary material

10545_2017_105_MOESM1_ESM.docx (54.3 mb)
ESM 1 (DOCX 55644 kb)

References

  1. Bolte S, Cordelieres FP (2006) A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224(Pt 3):213–232.  https://doi.org/10.1111/j.1365-2818.2006.01706.x CrossRefPubMedGoogle Scholar
  2. Cellini B, Bertoldi M, Montioli R, Paiardini A, Borri Voltattorni C (2007) Human wild-type alanine:glyoxylate aminotransferase and its naturally occurring G82E variant: functional properties and physiological implications. Biochem J 408(1):39–50.  https://doi.org/10.1042/BJ20070637 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Cellini B, Lorenzetto A, Montioli R, Oppici E, Voltattorni CB (2010) Human liver peroxisomal alanine:glyoxylate aminotransferase: different stability under chemical stress of the major allele, the minor allele, and its pathogenic G170R variant. Biochimie 92(12):1801–1811.  https://doi.org/10.1016/j.biochi.2010.08.005 CrossRefPubMedGoogle Scholar
  4. Cellini B, Montioli R, Bianconi S, Lopez-Alonso JP, Voltattorni CB (2008) Construction, purification and characterization of untagged human liver alanine-glyoxylate aminotransferase expressed in Escherichia Coli. Protein Peptide Lett 15(2):153–159CrossRefGoogle Scholar
  5. Cellini B, Montioli R, Oppici E, Astegno A, Voltattorni CB (2013) The chaperone role of the pyridoxal 5′-phosphate and its implications for rare diseases involving B6-dependent enzymes. Clin Biochem.  https://doi.org/10.1016/j.clinbiochem.2013.11.021
  6. Cellini B, Montioli R, Paiardini A, Lorenzetto A, Maset F, Bellini T, Oppici E, Voltattorni CB (2010) Molecular defects of the glycine 41 variants of alanine glyoxylate aminotransferase associated with primary hyperoxaluria type I. Proc Natl Acad Sci U S A 107(7):2896–2901.  https://doi.org/10.1073/pnas.0908565107 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Cellini B, Montioli R, Paiardini A, Lorenzetto A, Voltattorni CB (2009) Molecular insight into the synergism between the minor allele of human liver Peroxisomal Alanine:Glyoxylate Aminotransferase and the F152I mutation. J Biol Chem 284(13):8349–8358.  https://doi.org/10.1074/jbc.M808965200 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Cellini B, Montioli R, Voltattorni CB (2011) Human liver peroxisomal alanine:glyoxylate aminotransferase: characterization of the two allelic forms and their pathogenic variants. Biochim Biophys Acta 1814(11):1577–1584.  https://doi.org/10.1016/j.bbapap.2010.12.005 CrossRefPubMedGoogle Scholar
  9. Cellini B, Oppici E, Paiardini A, Montioli R (2012) Molecular insights into primary hyperoxaluria type 1 pathogenesis. Front Biosci 17:621–634CrossRefGoogle Scholar
  10. Chen R, Li L, Weng Z (2003) ZDOCK: an initial-stage protein-docking algorithm. Proteins 52(1):80–87.  https://doi.org/10.1002/prot.10389 CrossRefPubMedGoogle Scholar
  11. Danpure CJ (2004) Molecular aetiology of primary hyperoxaluria type 1. Nephron Exp Nephrol 98(2):e39–e44.  https://doi.org/10.1159/000080254 CrossRefPubMedGoogle Scholar
  12. Danpure CJ (2005) Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am J Nephrol 25(3):303–310.  https://doi.org/10.1159/000086362 CrossRefPubMedGoogle Scholar
  13. Dell'orco D (2009) Fast predictions of thermodynamics and kinetics of protein-protein recognition from structures:from molecular design to system biology. Mol BioSyst 5(4):323–334CrossRefPubMedGoogle Scholar
  14. Dell'orco D, De Benedetti PG, F F (2007) In silico screening of mutational effects on enzyme-proteic inhibitor affinity: a docking based approach. BMC Struct Biol 7 (37)Google Scholar
  15. Dell'Orco D, De Benedetti PG, Fanelli F (2007) In silico screening of mutational effects on transmembrane helix dimerization: insights from rigid-body docking and molecular dynamics simulations. J Phys Chem B 111 (30):9114-9124.  https://doi.org/10.1021/jp071383r
  16. Dell'Orco D, Casciari D, Fanelli F (2008) Quaternary structure predictions and estimation of mutational effects on the free energy of dimerization of the OMPLA protein. J Struct Biol 163(2):155–162.  https://doi.org/10.1016/j.jsb.2008.05.006 CrossRefPubMedGoogle Scholar
  17. Dell'Orco D, Seeber M, De Benedetti PG, Fanelli F (2005) Probing fragment complementation by rigid-body docking: in silico reconstitution of calbindin D9k. J Chem Inf Model 45(5):1429-1438.  https://doi.org/10.1021/ci0501995
  18. di Salvo ML, Contestabile R, Safo MK (2011) Vitamin B(6) salvage enzymes: mechanism, structure and regulation. Biochim Biophys Acta 1814(11):1597–1608.  https://doi.org/10.1016/j.bbapap.2010.12.006 CrossRefPubMedGoogle Scholar
  19. Dindo M, Montioli R, Busato M, Giorgetti A, Cellini B, Borri Voltattorni C (2016) Effects of interface mutations on the dimerization of alanine glyoxylate aminotransferase and implications in the mistargeting of the pathogenic variants F152I and I244T. Biochimie 131:137–148.  https://doi.org/10.1016/j.biochi.2016.10.001 CrossRefPubMedGoogle Scholar
  20. Fargue S, Lewin J, Rumsby G, Danpure CJ (2013) Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J Biol Chem 288(4):2475–2484.  https://doi.org/10.1074/jbc.M112.432617 CrossRefPubMedGoogle Scholar
  21. Fodor K, Wolf J, Erdmann R, Schliebs W, Wilmanns M (2012) Molecular requirements for peroxisomal targeting of alanine-glyoxylate aminotransferase as an essential determinant in primary hyperoxaluria type 1. PLoS Biol 10(4):e1001309.  https://doi.org/10.1371/journal.pbio.1001309 CrossRefPubMedPubMedCentralGoogle Scholar
  22. Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, Hoppe B (2014) Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol : CJASN 9(3):468–477.  https://doi.org/10.2215/CJN.06820613 CrossRefPubMedPubMedCentralGoogle Scholar
  23. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372(3):774–797.  https://doi.org/10.1016/j.jmb.2007.05.022 CrossRefPubMedGoogle Scholar
  24. Lumb MJ, Drake AF, Danpure CJ (1999) Effect of N-terminal alpha-helix formation on the dimerization and intracellular targeting of alanine:glyoxylate aminotransferase. J Biol Chem 274(29):20587–20596CrossRefPubMedGoogle Scholar
  25. Manning LR, Dumoulin A, Jenkins WT, Winslow RM, Manning JM (1999) Determining subunit dissociation constants in natural and recombinant proteins. Methods Enzymol 306:113–129CrossRefPubMedGoogle Scholar
  26. Merril AHJR, Henderson JM (1990) Vitamin B6 metabolism in human liver. Ann N Y Acad Sci 585:110–117CrossRefGoogle Scholar
  27. Monico CG, Olson JB, Milliner DS (2005) Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am J Nephrol 25(2):183–188.  https://doi.org/10.1159/000085411 CrossRefPubMedGoogle Scholar
  28. Montioli REO, Dindo M, Roncador A, Gotte G, Cellini B, Borri Voltattorni C (2015) Misfolding caused by the pathogenic mutation G47R on the minor allele of alanine:glyoxylate aminotransferase and chaperoning activity of pyridoxine. Biochim Biophys ActaGoogle Scholar
  29. Oppici E, Fargue S, Reid SR, Mills PB, Clayton PT, Danpure CJ, B. C (2015) Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing hyperoxaluria type I. Hum Mol Genet 24 (19):5500-5511Google Scholar
  30. Oppici E, Fodor K, Paiardini A, Williams C, Voltattorni CB, Wilmanns M, Cellini B (2013) Crystal structure of the S187F variant of human liver alanine: glyoxylate [corrected] aminotransferase associated with primary hyperoxaluria type I and its functional implications. Proteins 81(8):1457–1465.  https://doi.org/10.1002/prot.24300 CrossRefPubMedPubMedCentralGoogle Scholar
  31. Oppici E, Montioli R, Cellini B (2015) Liver peroxisomal alanine:glyoxylate aminotransferase and the effects of mutations associated with primary Hyperoxaluria type I: an overview. Biochim Biophys Acta 1854(9):1212–1219.  https://doi.org/10.1016/j.bbapap.2014.12.029 CrossRefPubMedGoogle Scholar
  32. Oppici E, Roncador A, Montioli R, Bianconi S, Cellini B (2013) Gly161 mutations associated with primary Hyperoxaluria type I induce the cytosolic aggregation and the intracellular degradation of the apo-form of alanine:glyoxylate aminotransferase. Biochim Biophys Acta 1832(12):2277–2288.  https://doi.org/10.1016/j.bbadis.2013.09.002 CrossRefPubMedGoogle Scholar
  33. Oppici EM, R. Cellini B. (2015) Liver peroxisomal alanine:glyoxylate aminotransferase and the effects of mutations associated with primary Hyperoxaluria type I: an overview. Biochim Biophys Acta 1854(9):1212–1219CrossRefPubMedGoogle Scholar
  34. Osswald H, Hautmann T (1979) Renal elimination kinetics and plasma half-life of oxalate in man. Urol Int 34(6):440–450CrossRefPubMedGoogle Scholar
  35. Pey AL, Salido E, Sanchez-Ruiz JM (2011) Role of low native state kinetic stability and interaction of partially unfolded states with molecular chaperones in the mitochondrial protein mistargeting associated with primary hyperoxaluria. Amino acids 41(5):1233–1245.  https://doi.org/10.1007/s00726-010-0801-2 CrossRefPubMedGoogle Scholar
  36. Purdue PE, Takada Y, Danpure CJ (1990) Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol 111(6 Pt 1):2341–2351CrossRefPubMedGoogle Scholar
  37. The Pymol Molecular Graphics System, version 1.8 Schrondinger, LLCGoogle Scholar
  38. Zhang X, Roe SM, Hou Y, Bartlam M, Rao Z, Pearl LH, Danpure CJ (2003) Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1. J Mol Biol 331(3):643–652CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM 2017

Authors and Affiliations

  1. 1.Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biological ChemistryUniversity of VeronaVeronaItaly
  2. 2.Department of Experimental MedicineUniversity of PerugiaPerugiaItaly

Personalised recommendations